Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Swiss Exchange  >  Novartis AG    NOVN   CH0012005267

News SummaryMost relevantAll newsSector newsTweets 


share with twitter share with LinkedIn share with facebook
share via e-mail
06/29/2016 | 01:00pm CET

As part of the Novartis Group's 20th annual Community Partnership Day, a group of employees spent a workday at The Land Conservancy of New Jersey in Boonton.

The Land Conservancy of New Jersey is a nonprofit, member supported land trust, dedicated to preserving and protecting open spaced lands and valuable water resources.

Novartis associates raked, planted, cleared debris and brush to beautify the organization's headquarters, WildAcres, a 44-acre public park.

Worldwide, more than 27,500 Novartis associates are dedicating an estimated 220,000 hours to volunteer with charitable causes in their communities to celebrate Community Partnership Day.

These Novartis Pharmaceuticals Corporation volunteers were among more than 5,000 associates in the U.S. who provided hands-on support that benefited more than 175 nonprofit agencies.

Community Partnership Day aims to provide opportunities for associates to give their time, expertise and ideas to volunteering efforts that foster a deeper connection with the patients we support and in the communities where we live.

"Community Partnership Day has been a traditional day of volunteer service at Novartis for 20 years, bringing together associates around the world and across functions to support our nonprofit partners and the important work that they do," said Amy Fry, vice president, communications and patient relations, Novartis Pharmaceuticals Corporation. "It's a fun and rewarding day to volunteer together and support our mission of discovering new ways to extend and improve people's lives."

© (c) 2016 The Neighbor News, North Jersey Media Group, Inc. All Rights Reserved., source Newspapers

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on NOVARTIS AG
06:44p NOVARTIS : Global Alprazolam Market 2017 - Endo, Mylan, Sandoz, Actavis, Apotex
06:21p NOVARTIS : Kisqali® ribociclib, LEE011 receives FDA approval as first-line treat..
03:59p OTSUKA : Ribociclib (LEE011) Receives Regulatory Approval in U.S. as a First-Lin..
03:20p NOVARTIS : Serelaxin Setback Puts Focus On Entresto
07:16a NOVARTIS : Alcon receives US FDA approval for new AcrySof® IQ ReSTOR® +2.5 Multi..
03/22 Global Inhalation & Nasal Spray Generic Drugs Market- Teva, Allergan PLC, Cip..
03/22 NOVARTIS` : Cosentyx is first and only IL-17A inhibitor to potentially modify th..
03/22 NOVARTIS : provides update on Phase III study of RLX030 (serelaxin) in patients ..
03/21 IMS HEALTH : Glenmark gets tentative nod from USFDA for Fingolimod capsules
03/21 NOVARTIS : ' Cosentyx is first and only IL-17A inhibitor to potentially modify t..
More news
Sector news : Pharmaceuticals - NEC
11:53a TEVA PHARMACEUTICAL INDUSTRIES : Pharm says media reports of up to 6,000 layoffs..
03/22 MYLAN : recalls 81,000 EpiPens outside U.S. after reports of failure
03/21DJSANOFI'S PRESCRIPTION FOR GROWTH : Drug Sales in the Middle Kingdom
03/20 FTSE rises to record close after Article 50 trigger date set
03/17DJPFIZER : Files 8K - Other Events
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
03/22 Serelaxin Setback Puts Focus On Entresto
03/22 BIOLINERX : Update And Preview Of The Company's Q4 And FY 2016 Financial Results..
03/22 Novartis' serelaxin flunks late-state heart failure study; shares ease a frac..
03/21 ABBVIE : Good For Value, Good For Growth
03/21 UPCOMING EVENTS : Alder's Migraine Test, Paratek's Antibiotic
Financials ($)
Sales 2017 48 429 M
EBIT 2017 11 388 M
Net income 2017 7 506 M
Debt 2017 15 034 M
Yield 2017 3,81%
P/E ratio 2017 22,47
P/E ratio 2018 19,82
EV / Sales 2017 4,32x
EV / Sales 2018 4,11x
Capitalization 194 072 M
More Financials
Duration : Period :
Novartis AG Technical Analysis Chart | NOVN | CH0012005267 | 4-Traders
Full-screen chart
Technical analysis trends NOVARTIS AG
Short TermMid-TermLong Term
Technical analysis
Income Statement Evolution
More Financials
Mean consensus HOLD
Number of Analysts 32
Average target price 80,4 $
Spread / Average Target 8,6%
Consensus details
EPS Revisions
More Estimates Revisions
Joseph Jimenez Chief Executive Officer
Hans Jörg Reinhardt Independent Non-Executive Chairman
Harry Kirsch Chief Financial Officer
Vasant Narasimhan Chief Medical Officer & Head-Drug Development
Srikant Madhav Datar Independent Non-Executive Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
NOVARTIS AG0.47%194 072
JOHNSON & JOHNSON9.59%342 277
ROCHE HOLDING LTD.7.52%217 164
PFIZER INC.6.13%205 273
MERCK & CO., INC.7.86%174 344
SANOFI7.63%115 490
More Results